Nicotine Addiction Clinical Trial
Official title:
Nicotine Reinforcement and Aversion in Young Adult Light Smokers
The proposed study will examine the threshold for nicotine self-administration (NSA) using five different nicotine doses in young adult male and female non-dependent smokers (light and intermittent smokers or LITS). We propose a double-blind, placebo-controlled study that will enroll 195 individuals, targeting a total of 72 completers (36 male and 36 females). In each of the five experimental sessions, smokers will be randomly assigned to one of the five doses of nicotine (0.0125, 0.025, 0.05, 0.1 and 0.2 mg/70 kg). The highest dose, 0.2 mg/70 kg, corresponds to nicotine delivered by about one or two puffs of a cigarette. At the beginning of each experimental session, smokers will sample the assigned both the nicotine dose for that experimental session, and the placebo (saline) dose, followed by the opportunity to choose between nicotine and placebo for a total of ten choices over a 150-minute period. The main outcomes will be threshold dose (the minimum dose of nicotine that is self-administered more than placebo) and the slope of dose-response for nicotine self-administration (changes in nicotine self-administration per unit change in nicotine dose). We will also collect measures of nicotine intake (cotinine), nicotine clearance (3-hydroxycotinine (3-HC) / cotinine), and self-report drug effects
Aim #1: To assess the threshold reinforcing dose and dose-effect curve for IV NSA at low doses in young adult LITS. Hypothesis #1A: The threshold reinforcing doses for IV NSA will be between 0.0125 to 0.1 mg/70 kg. Hypothesis #1B: The dose-effect curve for NSA will differ between males and females with relatively flat curve in female smokers. Aim #2: To assess the threshold and dose-effect curve for the positive and negative/aversive subjective effects of IV nicotine at low doses and its relationship to nicotine reinforcement. Hypothesis #2 A: The threshold for the positive effects will be between 0.0125 to 0.1 mg/70 kg, for the negative/aversive effect it will be ≥ 0.1 mg/70 kg. Hypothesis #2B: Nicotine reinforcement will be positively correlated with the positive and negatively correlated with the negative/aversive subjective effects of IV nicotine. Exploratory Aims: To examine the influence of nicotine clearance rate on nicotine reinforcement threshold and dose-effect curve. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02643914 -
Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings
|
N/A | |
Completed |
NCT02153749 -
Effects of Brief Training on Craving Regulation
|
N/A | |
Recruiting |
NCT05530577 -
Effects of Semaglutide on Nicotine Intake
|
Phase 2 | |
Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A | |
Completed |
NCT03694327 -
Innovative Digital Therapeutic for Smoking Cessation
|
N/A | |
Completed |
NCT01944423 -
Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine
|
Early Phase 1 | |
Completed |
NCT01704573 -
Nicotinic Receptor Levels After Stopping Smoking
|
N/A | |
Active, not recruiting |
NCT01015170 -
STOP Study: Effectiveness of Zyban in a Clinical Population
|
Phase 4 | |
Completed |
NCT03281629 -
Circuitry-Guided Smoking Cessation in Schizophrenia
|
N/A | |
Recruiting |
NCT06291584 -
Effects of Exercises on Functional Capacity
|
N/A | |
Withdrawn |
NCT06259630 -
Nicotine Virtual Reality Conditioned Place Preference
|
Phase 4 | |
Completed |
NCT02624284 -
tDCS Effects on Resisting Smoking: Dose Ranging Study
|
N/A | |
Active, not recruiting |
NCT02837510 -
Neural Mechanisms Associated With Risk of Smoking Relapse
|
N/A | |
Completed |
NCT02656745 -
Clinical Trial of Smoking Cessation Mobile Phone Program
|
N/A | |
Completed |
NCT01062932 -
Investigation of Cycloserine as a Smoking Cessation Treatment
|
Phase 1 | |
Completed |
NCT03069482 -
Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness
|
Phase 1 | |
Completed |
NCT02870218 -
Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use
|
Phase 2 | |
Terminated |
NCT01756053 -
Effects of ABT-089 on Smoking Abstinence Symptoms and Reward
|
Phase 2 | |
Completed |
NCT01252966 -
Cognitive Training for Nicotine Dependence
|
N/A | |
Active, not recruiting |
NCT04946825 -
Quit Smoking Study for People Who Use E-Cigarettes
|
Phase 2 |